Thursday, March 13, 2025 12:43:11 PM
Ironically, this is probably the most honest/accurate statement they've made in years.
Over the past several years, we've all seen plenty of instances where the Company makes a bold statement about something (Buyback, CBD, Brainwise, the SD Facility, etc.) with grandiose predictions about what it will mean, only to walk it back and walk away when they realize that there are broader implications. It sounds like this time around maybe, just maybe, they began to consult with appropriate SMEs to get a picture of how best to monetize ABBIE. Granted, they still managed to shoot first and ask questions later, but it sounds like they might have a chance to reload and give it a go.
Over the past several years, we've all seen plenty of instances where the Company makes a bold statement about something (Buyback, CBD, Brainwise, the SD Facility, etc.) with grandiose predictions about what it will mean, only to walk it back and walk away when they realize that there are broader implications. It sounds like this time around maybe, just maybe, they began to consult with appropriate SMEs to get a picture of how best to monetize ABBIE. Granted, they still managed to shoot first and ask questions later, but it sounds like they might have a chance to reload and give it a go.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
